Clinical trials: Apixaban
Venous Thromboembolism, Menstruation
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.
- Trial name
- (RAMBLE) (NCT02829957)
- Testing
- Apixaban, Rivaroxaban
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Indiana University
Anticoagulants and Thrombotic Disorders
Pharmacokinetics Study Of Rivaroxaban and Apixaban in Cancer Patients
Direct oral anticoagulants (DOACs) are now recommended as a first-line option in cancer patients with venous thromboembolism or atrial fibrillation.
- Trial name
- EPRAPAC (NCT05819736)
- Testing
- Monitoring
- Where
- France
- Volunteers
- 193 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Atrial Fibrillation
Perioperative Anticoagulant Use for Surgery Evaluation Study
The aim of the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study, is to establish a safe, standardized protocol for the perioperative management of patients with atrial fibrillation (AF) who are receiving a…
- Trial name
- PAUSE (NCT02228798)
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 3,135 people
- Sponsor
- McMaster University
Venous Thromboembolism
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer
Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study
- Trial name
- CARAVAGGIO (NCT03045406)
- Testing
- Apixaban, Dalteparin
- Where
- 127 sites in United States, Belgium and 9 more
- Volunteers
- 1,170 people
- Sponsor
- Fadoi Foundation, Italy
Anticoagulants
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Single-institution uncontrolled open-label trial.
- Trial name
- NCT05319340
- Testing
- prescribing anticoagulant therapy
- Volunteers
- 1,000 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Deep Vein Thrombosis, Pulmonary Embolism
The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-VTE study is a nationwide cluster randomized cross-over study comparing efficacy and safety of…
- Trial name
- DANNOAC-VTE (NCT03129555)
- Testing
- Dabigatran Etexilate Oral Capsule, Rivaroxaban Oral Tablet, Edoxaban Oral Tablet
- Where
- 26 sites in Denmark
- Volunteers
- 5,000 people
- Sponsor
- Herlev and Gentofte Hospital
COVID-19
A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan
The purpose of this study is to describe demographic and clinical characteristics of participants who are hospitalized due to coronavirus 2019 (COVID-19), treatment use for COVID-19 and COVID-19 symptoms, and composite outcomes…
- Trial name
- NCT04828772
- Where
- 2 sites in Japan
- Volunteers
- 9,282 people
- Sponsor
- Bristol-Myers Squibb
Anticoagulant, Apixaban
A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity
A prospective cohort study to determine whether a high body weight (BMI equal to or greater than 35 kg / m 2) has an effect on anticoagulant Apixaban level in the blood of patients with atrial fibrillation.
- Conditions
- Anticoagulant, Apixaban, Obesity
- Trial name
- NCT03893591
- Testing
- Anti Xa levels
- Where
- Israel
- Volunteers
- 82 people
- Sponsor
- HaEmek Medical Center, Israel
Spinal Cord Injuries, Venous Thromboembolism
Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury
Thromboprophylaxis options are limited for patients with acute spinal cord injury (SCI) and there are no studies on direct oral anticoagulants (DOACs) for thromboprophylaxis in this population.
- Trial name
- NCT03200613
- Testing
- Apixaban, Low molecular weight heparin
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- McMaster University
Ischemic Stroke
Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake
DO-IT is an international, multicenter, prospective, two-arm, randomized, open label, blinded endpoint superiority trial determining the safety and efficacy of intravenous thrombolysis (IVT) in participants experiencing an acute…
- Trial name
- DO-IT (NCT06571149)
- Testing
- Tenecteplase or Alteplase
- Where
- 109 sites in Austria, Belgium and 10 more
- Volunteers
- 906 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Atrial Fibrillation (AF)
Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)
Patients taking Factor Xa inhibitors (Apixaban, Rivaroxaban) in atrial fibrillation will be conducted a follow-up investigation on systemic embolism and bleeding events.
- Trial name
- NCT06779695
- Where
- South Korea
- Volunteers
- 2,000 people
- Sponsor
- Korea University Anam Hospital
Covid19, Thrombosis
Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19
Randomized, double-blinded, placebo-controlled trial comparing oral anticoagulation with placebo for community-dwelling patients with symptomatic COVID-19 infection and risk factors for thrombosis.
- Trial name
- APOLLO (NCT04746339)
- Testing
- Apixaban 2.5 MG
- Where
- 4 sites in Brazil
- Volunteers
- 411 people
- Sponsor
- Brazilian Clinical Research Institute
Coronary Artery Disease, High On-treatment Platelet Reactivity (HTPR)
Effect of Two Weeks of Low-Dose Apixaban on Platelet Reactivity in Patients With Stable Coronary Artery Disease on Dual Antiplatelet Therapy (Aspirin and Clopidogrel)
The goal of this clinical trial is to learn whether a low dose of apixaban, a blood-thinning medicine, changes how active the platelets are in adults with stable coronary artery disease who are already taking aspirin and…
- Trial name
- ACER (NCT07853612)
- Testing
- Apixaban
- Where
- Trinidad and Tobago
- Volunteers
- 16 people
- Sponsor
- The University of The West Indies
Anticoagulation
Adherence of Apixaban and Warfarin in Patients With Arterial Fibrillation in Real-world Setting in Sweden
This will be a retrospective cohort study using national register linkage data (including prescription, inpatient, mortality, and socioeconomic data). The study period will be from May 29, 2013 to June 30, 2015.
- Trial name
- NCT02492828
- Volunteers
- 41,000 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism, Anticoagulants
Apixaban for Extended Anticoagulation (APIDULCIS)
The study aims at optimizing the long-term and extended management of patients with a first episode of venous thromboembolism (proximal deep vein thrombosis with or without pulmonary embolism) (VTE).
- Trial name
- APIDULCIS (NCT03678506)
- Testing
- Apixaban
- Where
- Italy
- Volunteers
- 800 people
- Sponsor
- Arianna Anticoagulazione Foundation
Acute Coronary Syndrome
Phase III Acute Coronary Syndrome
The purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome
- Trial name
- APPRAISE-2 (NCT00831441)
- Testing
- Apixaban
- Where
- 1,012 sites in United States, Argentina and 38 more
- Volunteers
- 7,484 people
- Sponsor
- Bristol-Myers Squibb
Ischemic Stroke
Impact of Apixaban on Clinical Outcome of the Patients With Large Vessel Occlusion or Stenosis Trial
The aim of this study is to investigate the clinical events of the patients with acute cerebral large vessel occlusion or stenosis and atrial fibrillation, treated by apixaban within 14 days after onset.
- Trial name
- ALVO (NCT02818868)
- Testing
- apixisaban
- Where
- Japan
- Volunteers
- 700 people
- Sponsor
- Hyogo Medical University
Deep Vein Thrombosis, Pulmonary Embolism
Early Post-Marketing Study of ELIQUIS (Apixaban) in Mexico
The primary objective of the study is to report adverse events of on-treatment AEs by the treating physicians during a specified 24-month study period in patients with venous thromboembolism at the sentinel site(s) for the…
- Trial name
- NCT02345343
- Testing
- Apixaban
- Where
- Mexico
- Volunteers
- 100 people
- Sponsor
- Bristol-Myers Squibb
Stroke
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
Objectives Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
- Trial name
- ARCADIA (NCT03192215)
- Testing
- Apixaban, Aspirin
- Where
- 177 sites in United States, Canada
- Volunteers
- 1,015 people
- Sponsor
- Columbia University
Wound Bleeding
Treatment of Post-Punch Biopsy Bleeding in Apixaban-Treated Patients Using Self-Administered BXP154B
The goal of this clinical trial is to test if the study drug, BXP154B works to stop bleeding from a minor wound in patients that are on apixaban for anticoagulant therapy.
- Trial name
- NCT06205615
- Testing
- BXP154B, Punch Biopsy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Bio 54, LLC